Concert Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference
Lexington, MA - Concert Pharmaceuticals, Inc. announced today that it will be presenting at the Third Annual JMP Securities Healthcare Focus Conference, being held at the Le Parker Meridien in New York City. Roger Tung, Ph.D., President and Chief Executive Officer of Concert, will present an overview of the Company on Monday, October 6, 2008 at 4:00 p.m. (ET).
Concert Pharmaceuticals, Inc. is a clinical stage biotechnology company dedicated to creating medically and commercially important new medicines through a novel scientific approach utilizing the naturally-occurring element deuterium. Concert applies its innovative platform to create highly differentiated compounds based on well-understood biological targets and drug molecules, yielding a rich pipeline of new chemical entities (NCEs). Concert leverages decades of pharmaceutical experience to create drug candidates with potential for best-in-class efficacy and safety, while reducing R&D risk, time, and expense. The Company has over 100 patent applications for new drug candidates addressing a broad range of therapeutic areas, including vasomotor symptoms, HIV/AIDS and fibrotic diseases, among others. Since its inception in 2006, Concert has raised more than $96 million and has been financed by leading venture capitalists and institutional investors. A complete listing of Concert’s shareholders and additional corporate information is available online at http://www.concertpharma.com.
CoNCERT and CoNCERT Pharmaceuticals are trademarks of Concert Pharmaceuticals, Inc.